Shai Kalansky

Shai Kalansky

Education

University of California, San Diego (B.A., 2003)
Georgetown University Law Center (J.D., 2008)

Bar Admissions

New York
California

Shai Kalansky focuses his practice on corporate and transactional matters, including mergers, acquisitions, venture capital financings, and securities offerings, for public and private companies. His clients are U.S. and non-U.S. entities in the high tech, consumer products, life sciences, and healthcare industries.

Mr. Kalansky represents both buyers and sellers in acquisitions and dispositions. He assists investors, public and private companies with a broad range of securities offerings, including venture capital financings, registered direct offerings, PIPE transactions and underwritten deals. He also acts as outside general counsel for companies in which capacity he advises clients with respect to licensing matters, commercial contracts and employment issues.

Mr. Kalansky is fluent in Hebrew and conversant in Spanish.

The Pill Club
Represented The Pill Club in several financing rounds and certain other corporate matters.


MYT Food Group
Represented MYT in its $190 million acquisition of Papa Murphy’s Pizza (NASDAQ: FRSH).


ACEA Biosciences, Inc.
Represented ACEA Biosciences, Inc. in its US$250 million acquisition by Agilent Technologies Inc. (NYSE: A).


Cherokee Inc.’s Acquisition and Simultaneous Disposition of Hi-Tec
Represented Cherokee in its acquisition of Hi-Tec Sports International Holdings B.V. and its simultaneous disposition of various operating assets in the United States, Canada, Europe and Africa.


Sale of California Cryobank to GI Partners
Represented California Cryobank in its sale to GI Partners.


Sale of Abrams Artists Agency
Represented Harry Abrams in the sale of Abrams Artists Agency.


Natel Engineering Company’s $280 million acquisition of OnCore Manufacturing
Represented Natel in its acquisition of OnCore Manufacturing.


Sale of Biotix
Represented the sellers of Biotix Holdings Inc. in their sale of all outstanding equity of Biotix to Mettler-Toledo, LLC.


Fulgent Genetics Initial Public Offering
Represented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, as issuer’s counsel on its initial public offering.


Fulgent Genetics Preferred Financing
Represented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, in its preferred stock financing of over $27 million.


Solarflare Communications, Inc. Preferred Financing
Represented Solarflare Communications, Inc., a leading provider of application-intelligent networking I/O software and hardware, on numerous preferred stock financings totaling over $52 million.


Emerald Health Pharmaceuticals Regulation A+ Offering
Represented Emerald Health Pharmaceuticals Inc., which is developing synthetic cannabinoid-derived drugs for CNS, autoimmune, and other diseases, in its Tier II Regulation A+ offering.


AMN Healthcare’s $160 million acquisition of B.E. Smith
Represented AMN in its acquisition of B.E. Smith.


AMN Healthcare’s $82 million acquisition of Onward Healthcare
Represented AMN in its acquisition of Onward Healthcare.


Sale of Mo Bio Laboratories
Represented the sellers of Mo Bio Laboratories in their sale of all outstanding equity of Mo Bio to Qiagen.


Netlist’s public offerings
Represented Netlist (NASDAQ: NLST), a producer of next generation persistent memory solutions, in its public offerings of common stock and warrants.


Imprimis Pharmaceuticals, Inc. Acquisition of Compounding Pharmacy
Represented Imprimis in its acquisition of South Coast Specialty Compounding, Inc.


Hitachi Metals, Ltd. Licensing
Represented Hitachi Metals, Ltd. in connection with patent license agreements and settlement agreements concluded in relation to an investigation at the U.S. International Trade Commission involving infringement of certain Hitachi Metals sintered rare earth magnet patents.


MoFo ScaleUp

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.